Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
MIRA Pharmaceuticals Inc (NASDAQ:MIRA) stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro.
据Benzinga Pro的数据，纳斯达克（NASDAQ：MIRA）的MIRA药品股票周四交易较高，成交量为4790万。
The company announced new insights from additional recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2.
该公司宣布根据其新近收到的补充临床前研究数据获得新的机制和毒性数据方面的新观点，其新型口服氯胺酮类似物肯他米-2的候选药品。
Ketamir-2 is MIRA's drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders.
肯他米-2是MIRA正在研究作为治疗神经和神经精神紊乱的潜在治疗方案的药物候选。
Related: Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders.
相关：纳斯达克股票MIRA药品的口服氯胺酮类似物在神经精神紊乱方面显示出潜力。
The new preclinical study results announced are the latest in a string of research developments progressing MIRA's goal of submitting an Investigational New Drug Application (NDA) to the FDA for Ketamir-2 later this year.
新公布的临床前研究结果是连续一系列研究发展，推进MIRA今年晚些时候向FDA提交Ketamir-2的新药申请（NDA）目标的最新进展。
The latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the PCP-binding site of the NMDA complex.
最新的临床前数据显示，Ketamir-2是人类大脑中主要的兴奋性神经递质谷氨酸（glutamate）的NMDA受体的选择性抑制剂，特别是在NMDA复合物的PCP结合位点上发生作用。
Ketamir-2 has a 30-50-fold lower affinity to the PCP site than ketamine.
Ketamir-2对PCP位点的亲和力是氯胺酮的30-50倍。
The lower affinity is important because compounds may affect neurobehavioral functions at high affinity, potentially leading to side effects such as dissociation and hallucinations.
较低的亲和力很重要，因为化合物在高亲和力下可能影响神经行为功能，潜在地导致偏离和幻觉等副作用。
Unlike traditional ketamine, which also affects several other sites on the NMDA receptor and interacts with opioid receptors, dopamine and serotonin transporters, and various acetylcholine receptors, Ketamir-2 exhibits unique selectivity and does not interact with these additional receptor sites.
与传统的氯胺酮不同，氯胺酮也影响NMDA受体上的其他几个结合位点，与阿片受体、多巴胺和血清素转运体以及各种乙酰胆碱受体相互作用，而Ketamir-2表现出独特的选择性，并不与这些额外的受体位点相互作用。
Recently conducted toxicology studies in rats and dogs have shown no toxicity at very high doses of Ketamir-2.
最近进行的大鼠和狗的毒理学研究显示，Ketamir-2的很高剂量没有毒性。
These findings underscore Ketamir-2's favorable safety margin, further supported by its antidepressant and anxiolytic activities observed at oral doses five to tenfold lower than those tested in the toxicology studies.
这些发现强调了Ketamir-2的有利安全保障，进一步支持了其抗抑郁和抗焦虑的活性，在毒理学研究中测试剂量的五到十倍的口服剂量下观察到。
The company says that Ketamir-2 could potentially be beneficial in treating conditions like depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).
该公司表示，Ketamir-2在治疗忧郁症、耐药性忧郁症（TRD）和创伤后应激症（PTSD）方面有潜在益处。
Price Action: MIRA stock is up 38.8% at $3.27 at last check Thursday.
MIRA股票周四上涨38.8%，收于3.27美元。
- AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
- 艾伯维公司第二季度收益超出预期，因新型免疫和癌症药物销售强劲提高了年度利润。